全文获取类型
收费全文 | 384篇 |
免费 | 22篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 14篇 |
妇产科学 | 13篇 |
基础医学 | 30篇 |
口腔科学 | 10篇 |
临床医学 | 26篇 |
内科学 | 76篇 |
皮肤病学 | 13篇 |
神经病学 | 1篇 |
特种医学 | 63篇 |
外科学 | 40篇 |
综合类 | 24篇 |
预防医学 | 49篇 |
眼科学 | 1篇 |
药学 | 26篇 |
中国医学 | 7篇 |
肿瘤学 | 15篇 |
出版年
2022年 | 3篇 |
2019年 | 5篇 |
2018年 | 12篇 |
2017年 | 3篇 |
2016年 | 6篇 |
2015年 | 3篇 |
2014年 | 14篇 |
2013年 | 15篇 |
2012年 | 10篇 |
2011年 | 14篇 |
2010年 | 9篇 |
2009年 | 13篇 |
2008年 | 15篇 |
2007年 | 14篇 |
2006年 | 8篇 |
2005年 | 11篇 |
2004年 | 6篇 |
2003年 | 9篇 |
2002年 | 9篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 5篇 |
1998年 | 19篇 |
1997年 | 23篇 |
1996年 | 15篇 |
1995年 | 13篇 |
1994年 | 6篇 |
1993年 | 13篇 |
1992年 | 3篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1988年 | 8篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 19篇 |
1984年 | 8篇 |
1983年 | 5篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1979年 | 3篇 |
1978年 | 6篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1972年 | 2篇 |
1968年 | 5篇 |
1967年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有409条查询结果,搜索用时 8 毫秒
71.
72.
Cancer of the large intestine 总被引:1,自引:0,他引:1
L Simeonov G Gruev A Atanasov L Koshev I Khadzhiev 《Vestnik khirurgii imeni I. I. Grekova》1973,109(1):79-81
73.
74.
Antoon H van Lierop Neveen AT Hamdy Herman Hamersma Rutger L van Bezooijen Jon Power Nigel Loveridge Socrates E Papapoulos 《Journal of bone and mineral research》2011,26(12):2804-2811
Sclerosteosis is a rare bone sclerosing dysplasia, caused by loss‐of‐function mutations in the SOST gene, encoding sclerostin, a negative regulator of bone formation. The purpose of this study was to determine how the lack of sclerostin affects bone turnover in patients with sclerosteosis and to assess whether sclerostin synthesis is decreased in carriers of the SOST mutation and, if so, to what extent this would affect their phenotype and bone formation. We measured sclerostin, procollagen type 1 amino‐terminal propeptide (P1NP), and cross‐linked C‐telopeptide (CTX) in serum of 19 patients with sclerosteosis, 26 heterozygous carriers of the C69T SOST mutation, and 77 healthy controls. Chips of compact bone discarded during routine surgery were also examined from 6 patients and 4 controls. Sclerostin was undetectable in serum of patients but was measurable in all carriers (mean 15.5 pg/mL; 95% confidence interval [CI] 13.7 to 17.2 pg/mL), in whom it was significantly lower than in healthy controls (mean 40.0 pg/mL; 95% CI 36.9 to 42.7 pg/mL; p < 0.001). P1NP levels were highest in patients (mean 153.7 ng/mL; 95% CI 100.5 to 206.9 ng/mL; p = 0.01 versus carriers, p = 0.002 versus controls), but carriers also had significantly higher P1NP levels (mean 58.3 ng/mL; 95% CI 47.0 to 69.6 ng/mL) than controls (mean 37.8 ng/mL; 95% CI 34.9 to 42.0 ng/mL; p = 0.006). In patients and carriers, P1NP levels declined with age, reaching a plateau after the age of 20 years. Serum sclerostin and P1NP were negatively correlated in carriers and age‐ and gender‐matched controls (r = 0.40, p = 0.008). Mean CTX levels were well within the normal range and did not differ between patients and disease carriers after adjusting for age (p = 0.22). Our results provide in vivo evidence of increased bone formation caused by the absence or decreased synthesis of sclerostin in humans. They also suggest that inhibition of sclerostin can be titrated because the decreased sclerostin levels in disease carriers did not lead to any of the symptoms or complications of the disease but had a positive effect on bone mass. Further studies are needed to clarify the role of sclerostin on bone resorption. © 2011 American Society for Bone and Mineral Research 相似文献
75.
急性淋巴细胞白血病(上) 总被引:2,自引:0,他引:2
急性淋巴细胞白血病是淋巴前体细胞异常引起的恶性疾病,儿童与成人均可能发生。儿童发病高峰2~5岁。有效治疗的稳步进展使本病在儿童中的治愈率80%以上,同时为新的治疗方案提供了良机,新方案将保留我们在白血病无病生存病例中获得的治疗经验,同时减轻当前强化治疗方案中的毒副作用。 相似文献
76.
5 风险评估对病人的复发风险进行评估以确保只有高危病例才被施予极强治疗.研究表明采用成人方案治疗的青少年病人,其效果要显著差于使用儿童方案治疗的同年龄组. 相似文献
77.
Sabine Kopf Katharina Viola Atanas G. Atanasov Kanokwan Jarukamjorn Lucie Rarova Nicole Kretschy Mathias Teichmann Caroline Vonach Philipp Saiko Benedikt Giessrigl Nicole Huttary Ingrid Raab Sigurd Krieger Marc Schumacher Marc Diederich Miroslav Strnad Rainer de Martin Thomas Szekeres Walter Jäger Verena M. Dirsch Wolfgang Mikulits Michael Grusch Helmut Dolznig Georg Krupitza 《Archives of toxicology》2013,87(10):1851-1861
Metastases destroy the function of infested organs and are the main reason of cancer-related mortality. Heteronemin, a natural product derived from a marine sponge, was tested in vitro regarding its properties to prevent tumour cell intravasation through the lymph-endothelial barrier. In three-dimensional (3D) cell cultures consisting of MCF-7 breast cancer cell spheroids that were placed on lymph-endothelial cell (LEC) monolayers, tumour cell spheroids induce “circular chemorepellent-induced defects” (CCIDs) in the LEC monolayer; 12(S)-Hydroxyeicosatetraenoic acid (12(S)-HETE) and NF-κB activity are major factors inducing CCIDs, which are entry gates for tumour emboli intravasating the vasculature. This 3D co-culture is a validated model for the investigation of intravasation mechanisms and of drugs preventing CCID formation and hence lymph node metastasis. Furthermore, Western blot analyses, NF-κB reporter, EROD, SELE, 12(S)-HETE, and adhesion assays were performed to investigate the properties of heteronemin. Five micromolar heteronemin inhibited the directional movement of LECs and, therefore, the formation of CCIDs, which were induced by MCF-7 spheroids. Furthermore, heteronemin reduced the adhesion of MCF-7 cells to LECs and suppressed 12(S)-HETE-induced expression of the EMT marker paxillin, which is a regulator of directional cell migration. The activity of CYP1A1, which contributed to CCID formation, was also inhibited by heteronemin. Hence, heteronemin inhibits important mechanisms contributing to tumour intravasation in vitro and should be tested in vivo. 相似文献
78.
79.
Andreas Andreou Benjamin Struecker Nathanael Raschzok Felix Krenzien Philipp Haber Simon Wabitsch Christoph Waldbaur Eva-Maria Touet Anne-Christine Eichelberg Georgi Atanasov Matthias Biebl Marcus Bahra Robert Öllinger Moritz Schmelzle Johann Pratschke 《Surgical oncology》2018,27(4):751-758
Background
Minimal-invasive hepatectomy (MIH) has been increasingly performed for benign and malignant liver lesions with most promising results. However, the role of MIH for the treatment of patients with hepatocellular carcinoma (HCC) needs further investigation.Methods
Clinicopathological data of patients who underwent liver resection for HCC between 2005 and 2016 were assessed. Postoperative outcomes und long-term survivals of patients following MIH were compared with those of patients undergoing conventional open hepatectomy (OH) after 1:1 propensity score matching.Results
During the study period, 407 patients underwent liver resection for HCC with curative intent. Fifty-six patients underwent MIH and were compared with a matched cohort of 56 patients who underwent OH. The rate of patients with fibrosis/cirrhosis (82% vs. 86%, p?=?0.959), multiple lesions (32% vs. 32%, p?=?1.00), tumor size >30?mm (61% vs. 55%, p?=?0.566), and major resection (16% vs. 16%, p?=?1.00) was comparable between the two groups (MIH vs. OH). MIH was associated with lower 90-day complication rate (32% vs. 54%, p?=?0.022), lower postoperative major complication rate (14% vs. 30%, p?=?0.041), lower liver failure rate (0% vs. 7%, p?=?0.042), lower 90-day mortality rate (0 vs. 7%, p?=?0.042), and shorter length of hospital stay (9 vs. 12 days, p?=?0.009) compared to OH. After a median follow-up time of 51 months, MIH and OH showed comparable 5-year overall survival (54% vs. 41%, p?=?0.151), and 5-year disease-free survival rates (50% vs. 38%, p?=?0.956).Conclusions
MIH for HCC is associated with lower postoperative morbidity and mortality and shorter length of hospital stay, resulting in oncologic outcomes similar to those achieved with the established OH. Our findings suggest that MIH should be considered as the preferred method for the treatment of curatively resectable HCC. 相似文献80.
Validity of the Iwate criteria for patients with hepatocellular carcinoma undergoing minimally invasive liver resection 下载免费PDF全文